Vietnamese Pharmaceuticals Boost Profits by 21% Through Reduced Provision Accruals

Vietnam Pharmaceutical Corporation - JSC (UPCoM: DVN) has released its Q3/2025 consolidated financial report, revealing a 21% surge in net profit. This impressive growth is primarily attributed to reduced financial expenses and increased non-operating income from its subsidiaries.

0
11
DVN’s Q3/2025 Business Targets

In Q3, DVN reported net revenue exceeding 1.3 trillion VND, a 9% increase year-over-year. However, the cost of goods sold rose by 10%, slightly reducing gross profit to 126 billion VND.

A highlight of the quarter was a 16% rise in financial activity revenue to 39 billion VND, while financial expenses decreased by 24% to 28 billion VND. Additionally, profits from affiliated companies contributed 29 billion VND, a modest 3% increase. Coupled with a 37% surge in other income to 40 billion VND, DVN posted a net profit of nearly 73 billion VND, up 21%.

According to DVN, the profit increase was primarily due to lower financial expenses in Q3 (attributed to reduced provisions for financial investments compared to the same period last year) and increased other income from subsidiaries.

Despite the positive Q3 results, DVN‘s year-to-date performance has lagged due to high comparables from the previous year (record profits in 2024). Nine-month net revenue remained flat at over 3.97 trillion VND, with net profit declining 25% to 287 billion VND. The company has achieved nearly 67% of its revenue target and over 78% of its after-tax profit goal for the year.

Source: VietstockFinance

As of September 30, 2025, DVN‘s total assets reached 6.8 trillion VND, a 5% increase from the beginning of the year, with over 4.8 trillion VND in current assets, up 10%. Cash and cash equivalents stood at nearly 1.2 trillion VND, a 12% increase. Inventory rose by 14% to nearly 1.9 trillion VND.

Short-term receivables totaled over 1.7 trillion VND, a 5% increase, primarily from customer receivables.

On the liabilities side, total debt increased by nearly 10% to over 3.2 trillion VND, almost entirely short-term. Short-term loans rose by 20% to nearly 1.5 trillion VND, mostly from banks.

Châu An

– 10:29 30/10/2025

You may also like

Q3/2025 Financial Reports Due by October 28: Major Corporations Announce Earnings, OCB Reports Pre-Tax Profit Surge of Nearly 250%

Masan Hightech Materials (MSR) reported a pre-tax profit of VND 14 billion in Q3, a remarkable turnaround from a VND 292 billion loss in the same period last year. Meanwhile, PAN Group (PAN) saw a 16% decline in Q3 pre-tax profit to VND 305 billion. However, for the first nine months, PAN’s profit rose 3% to VND 848 billion.

Tanimex Announces 12.5% Cash Dividend Payout

Tanimex (HOSE: TIX) has announced the record date for its second dividend payment of 2025, offering a 12.5% cash dividend (VND 1,250 per share). The ex-dividend date is set for November 21, with payments expected to commence on December 24.

DIG Records Q3 Net Profit of Over 210 Billion VND from Lam Ha Center Point Transfer

Fueled by a remarkable third-quarter performance, Construction Development Investment Corporation (HOSE: DIG) witnessed a staggering 14-fold increase in consolidated net profit for the first nine months of the year compared to the same period last year.

Q3/2025 Financial Reports Deadline: Vincom Retail, Nam Long, DIG, Hoa Phat, and More Leading Enterprises Announce Updates by October 29th

In Q3/2025, Gelex’s pre-tax profit soared to VND 1,253 billion, marking a remarkable 149.7% increase compared to the same period last year. Meanwhile, PNJ’s after-tax profit for Q3/2025 reached VND 496 billion, a staggering 129.7% growth, equating to a daily profit of over VND 4.06 billion for the company.

Billionaire Nguyen Dang Quang’s Pork Business: Q3 Profits Surge Fivefold

Masan’s meat business segment delivered another quarter of robust performance in Q3, showcasing significant growth across both livestock farming and processed meat divisions. Concurrently, the company demonstrated effective management of financial expenses, further solidifying its market position.